| [1] |
Elizabeth AP, Angelo MDM. Epidemiology of inflammation and prostate cancer[J]. J Urol, 2004, 171(2 Pt 2): S36-S40.
|
| [2] |
谷淑燕, 韩日才, 司静懿, 等. 宫颈癌中乳头瘤病毒核酸的检测[J]. 病毒学报, 1986, 2(3): 260-262.
|
| [3] |
Eva S, James RW, Shu- HY, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer[J]. J Urol, 2018, 199(1): 161-171.
|
| [4] |
Gissmann L, Pfister H, Zur Hausen H. Human papilloma viruses (HPV): characterization of four different isolates[J]. Virology, 1977, 76(2): 569-580.
|
| [5] |
Zur Housen H. Papillomaviruses and cancer: from basic studies to clinical application[J]. Nat Rev Cancer, 2002, 2(5): 342-350.
|
| [6] |
Giorgio IR, Aldo EC, Rosita AC, et al. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis[J].Aging Male, 2020, 23(2): 132-138.
|
| [7] |
Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control[J]. Oncogene, 2002, 21(10): 1510-1517.
|
| [8] |
Dogra S, Bandi S, Viswanathan P, et al. Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16E6/E7 for further therapeutic directions in renal cell carcinoma[J]. Cancer Lett, 2015, 56(2): 953-961.
|
| [9] |
Kakisi OK, Robinson MJ, Tettmar KI, et al. The rise and fall of XMRV[J]. Transfus Med, 2013, 23(3): 142-151.
|
| [10] |
Robert S, Daniel JC, Kristy RB,et al. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors[J]. Proc Natl Acad Sci USA,2009,106(38):16351-16356.
|
| [11] |
Baig FA, Mirza T, Khanani R, et al. Detection of Xenotropic murine leukemia virus-related virus in prostate biopsy samples[J]. J Coll Physicians Surg Pak, 2014, 24(9): 636-639.
|
| [12] |
Baig FA, Mirza T, Hamid A, et al. Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer[J]. Turk J Urol, 2017, 43(3): 268-272.
|
| [13] |
Harriet CTG, Anne YW, David EN, et al. No evidence for infection of uk prostate cancer patients with xmrv, bk virus, trichomonas vaginalis or human papilloma viruses[J]. PLoS ONE, 2012, 7(3): e34221.
|
| [14] |
Ramon M, Robert HS, Eric AK, et al. No biological evidence of XMRV in blood or prostatic fluid from prostate cancer patients[J]. PLoS ONE, 2017, 7(5): e36073.
|
| [15] |
Balfour HHJ, Schmeling D, Grimm-Geris JM. The promise of a prophylactic Epstein-Barr virus vaccine[J]. Pediatr Res, 2020, 87(2): 345-352.
|
| [16] |
Iizasa H, Kim H, Kartika AV, et al. Role of viral and host micro rnas in immune regulation of epstein-barr virus-associated diseases[J]. Front Immunol, 2020, 11: 367.
|
| [17] |
刘春艳, 谢正德. EB病毒感染相关疾病的实验室诊断[J]. 中华实用儿科临床杂志, 2016, 31(22): 1691-1696.
|
| [18] |
郭建巍. EB病毒感染的核酸检测:标本类型的选择[J]. 分子诊断与治疗杂志, 2016, 8(3): 145-149.
|
| [19] |
Bergh J, Marklund I, Gustavsson C, et al. No link between viral findings in the prostate and subsequent cancer development[J]. Br J Cancer, 2007, 96(1): 137-9.
|
| [20] |
卓士超, 王衡. 隐匿性前列腺癌及其EBV、HPV蛋白的表达[J]. 齐齐哈尔医学院学报, 2009, 30(23): 2882-2883.
|
| [21] |
Layla AAKW, Basim SA, Dawood S. Impress of ebv rna (ebers) and p16 on grades of prostate carcinoma[J]. Med Microbiol Immun, 2018, 2(1): 1-5.
|
| [22] |
Brimo F, Montironi R, Egevad L, et al. Contemporary grading for prostate cancer: implications for patient care[J]. Eur Urol, 2013, 63(5): 892-901.
|
| [23] |
Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas[J]. Microbiol Mol Biol Rev, 1998, 62(4): 1094-1156.
|
| [24] |
Cimolai N. Do mycoplasmas cause human cancer[J]. Can J Microbiol, 2001, 47(8): 691-7.
|
| [25] |
Quirk JT, Kupinski JM, DiCioccio RA. Detection of mycoplasmal ribosomal dna sequences in ovarian tumors by nested PCR[J]. Gynecol Oncol, 2001, 83(3): 560-562.
|
| [26] |
李强, 程伟, 张洁, 等. 人前列腺癌组织中解脲支原体的检测[J]. 现代肿瘤医学, 2010, 18(5): 958-959.
|
| [27] |
Barykova YA, Logunov DY, Shmarov MM, et al. Association of Mycoplasma hominis infection with prostate cancer[J]. Oncotarget, 2011, 2(4): 289-97.
|
| [28] |
Khan S, Zakariah M, Rolfo C, et al. Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology[J]. Oncotarget, 2017, 8(19): 30830-30843.
|
| [29] |
Ketcham CM, Anai S, Reutzel R, et al. p37 Induces tumor invasiveness[J]. Mol Cancer Ther，2005, 4(7): 1031-1038.
|
| [30] |
Zakariah M, Khan S, Chaudhary AA, et al. To decipher the mycoplasma hominis proteins targeting into the endoplasmic reticulum and their implications in prostate cancer etiology using next-generation sequencing data[J]. Molecules, 2018, 23(5): 994.
|
| [31] |
Ge X, Wang X, Shen P. Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: A meta-analysis[J]. Biomed Rep, 2013, 1(3): 433-439.
|
| [32] |
Haid M, Sharon N. Immunofluorescent evidence of prior herpes simplex virus type-2 infection in prostate carcinoma[J]. Urology, 1984, 24(6): 623-625.
|
| [33] |
Korodi Z, Wang Xh, Tedeschi R, et al. No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study[J]. J infect Dis, 2005, 191(12): 2008-2011.
|
| [34] |
张东青, 吕家驹, 马道新, 等. 重组干扰素α-2a增强HSV-TK基因对前列腺癌细胞的体外杀伤作用[J]. 山东大学学报(医学版), 2005，43(8): 727-729+733.
|
| [35] |
Lei W, Jianfang N, Hiroaki W, et al. Oncolytic herpes simplex virus and pi3k inhibitor bkm120 synergize to promote killing of prostate cancer stem-like cells[J]. Mol Ther-Oncolytics, 2019, 13: 58-66.
|
| [36] |
Masafumi O, Takashi O, Michio H, et al. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207[J]. JPN J Cancer Res, 2000, 91(12): 1339-1344.
|
| [37] |
何必鸣, 陈锐, 孙颖浩. 长链非编码RNA作为诊断前列腺癌的标志物的现状[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2015, 9(3): 225-228.
|